Inducible Escherichia coli fermentation for increased plasmid DNA production

被引:62
作者
Carnes, Aaron E. [1 ]
Hodgson, Clague P. [1 ]
Williams, James A. [1 ]
机构
[1] Nat Technol Corp, Lincoln, NE 68521 USA
关键词
DNA vaccine; Escherichia coli; fermentation; gene therapy; plasmid DNA; vector;
D O I
10.1042/BA20050223
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bacterial plasmids are the vectors of choice for DNA vaccines and short-term gene therapeutics. Growing plasmid DNA by microbial (Escherichia coli) fermentation is usually combined with alkaline lysis/chromatography methods of purification. To date, typical plasmid fermentation media and processes result in yields of 100-250 mg of plasmid DNA/I of culture medium, using standard high-copy pUC origin-containing plasmids. In order to address this initial and yield-limiting upstream step, we identified novel fermentation control parameters for fed-batch fermentation. The resulting fermentation strategies significantly increased specific plasmid yield with respect to cell mass while enhancing plasmid integrity and maintaining supercoiled DNA content. Fed-batch fermentation yield exceeding 1000 mg of plasmid DNA/I was obtained after reduction of plasmid-mediated metabolic burden during growth, and yields up to 1500 mg of plasmid DNA/I have been achieved with optimized plasmid backbones. Interestingly, by inducing high plasmid levels after sufficient biomass accumulation at low temperature and restricted growth, cells were able to tolerate significantly higher plasmid quantities than cells grown by conventional processes. This S-10-fold increase in plasmid yield dramatically decreases plasmid manufacturing costs and improves the effectiveness of downstream purification by reducing the fraction of impurities.
引用
收藏
页码:155 / 166
页数:12
相关论文
共 47 条
[21]   Impact of plasmid size on cellular oxygen demand in Escherichia coli [J].
Kay, A ;
O'Kennedy, R ;
Ward, J ;
Keshavarz-Moore, E .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2003, 38 :1-7
[22]   Perspectives on plasmid-based gene therapy: challenges for the product and the process [J].
Kelly, WJ .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2003, 37 :219-223
[23]   High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation [J].
Lahijani, R ;
Hulley, G ;
Soriano, G ;
Horn, NA ;
Marquet, M .
HUMAN GENE THERAPY, 1996, 7 (16) :1971-1980
[24]   High cell-density culture of Escherichia coli [J].
Lee, SY .
TRENDS IN BIOTECHNOLOGY, 1996, 14 (03) :98-105
[25]   HIGH COPY NUMBER OF THE PUC PLASMID RESULTS FROM A ROM ROP-SUPPRESSIBLE POINT MUTATION IN RNA-II [J].
Lin-Chao, S ;
CHEN, WT ;
WONG, TT .
MOLECULAR MICROBIOLOGY, 1992, 6 (22) :3385-3393
[26]   EFFECT OF THE BACTERIAL-GROWTH RATE ON REPLICATION CONTROL OF PLASMID PBR322 IN ESCHERICHIA-COLI [J].
LINCHAO, S ;
BREMER, H .
MOLECULAR & GENERAL GENETICS, 1986, 203 (01) :143-149
[27]   Human clinical trials of plasmid DNA vaccines [J].
Liu, Margaret A. ;
Ulmer, Jeffrey B. .
ADVANCES IN GENETICS, 2005, 55 :25-40
[28]   RUNAWAY-REPLICATION PLASMIDS AS TOOLS TO PRODUCE LARGE QUANTITIES OF PROTEINS FROM CLONED GENES IN BACTERIA [J].
NORDSTROM, K ;
UHLIN, BE .
BIO-TECHNOLOGY, 1992, 10 (06) :661-666
[29]   Effects of growth medium selection on plasmid DNA production and initial processing steps [J].
O'Kennedy, RD ;
Baldwin, C ;
Keshavarz-Moore, E .
JOURNAL OF BIOTECHNOLOGY, 2000, 76 (2-3) :175-183
[30]   Effects of fermentation strategy on the characteristics of plasmid DNA production [J].
O'Kennedy, RD ;
Ward, JM ;
Keshavarz-Moore, E .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2003, 37 :83-90